Isomorphic Labs has raised $5 billion to advance its AI drug-discovery work and prepare drug candidates for clinical trials. The Series C round gives the company new funding to develop its drug-design engine and explore additional types of medicine.
Funding to advance the drug-design platform
The round was co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz joined as a new investor, alongside other participants. Existing backers also invested, including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.
The raise follows a $2.1 billion Series B round in May. Isomorphic said the new capital will support further development of its platform and expansion into more types of medicine. The company did not disclose its new valuation.
Bloomberg reported earlier this month that the lab was looking to raise funding at a $50 billion valuation. That figure was reported as a fundraising target; it is not a valuation Isomorphic has publicly disclosed in the source article.
How Isomorphic uses AI in drug design
Isomorphic builds an AI drug-design engine made up of simulation AI models. The models explore different areas of chemistry to help design drugs. The approach builds on DeepMind’s AlphaFold protein-folding AI model, which predicts the 3D structure of proteins from their genetic sequence.
In practical terms, the company is applying computational models to questions involved in designing potential medicines. The funding is intended to support the engine’s continued development, while the company works to take candidates toward clinical trials.
Isomorphic said its program has produced “positive preclinical results” in oncology and immunology. These results are at the preclinical stage, and the source does not describe clinical trial outcomes. The distinction matters: the announced goal is to move candidates toward trials, rather than report that they have already been tested in people.
Pharma partnerships and company leadership
The lab has struck deals with Eli Lilly, Novartis, and Johnson & Johnson. Those agreements place its AI drug-design work alongside established pharmaceutical companies, although the article does not provide details about the terms or specific medicines involved.
This is Isomorphic’s first fundraising round since founder and CEO Demis Hassabis left his position as head of DeepMind to focus on drug discovery. Hassabis moved into a chairman role at DeepMind. He and then-director of DeepMind John Jumper won the Nobel Prize in chemistry for the lab’s work on AlphaFold.
What the funding signals
The size of the round indicates substantial investor backing for Isomorphic’s plan to use AI in drug discovery. The company is pursuing two connected aims: improving the design engine and widening the kinds of medicine it can address.
The next stated milestone is bringing drug candidates to clinical trials. The source offers no timeline for that step and no disclosed valuation, so the funding announcement sets out the company’s direction more clearly than its near-term clinical schedule.